![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Efficacy and Safety of Elbasvir/Grazoprevir in Women Infected With Hepatitis C Virus Genotypes 1 or 4 and Coadministered Oral Contraceptives or Hormone Replacement Therapy
|
|
|
Reported by Jules Levin
EASL 2018 April 11-15 Paris France
Hezode C1; Kwo P2; Sperl J3; Dore G4; Hwang P5; Long J5; Yeh W5; Talwani R5; Robertson M5; Haber B5
1Service d'Hépatologie, Hôpital Henri-Mondor, AP-HP, Université Paris-Est, INSERM U955, Créteil, France; 2Division of Gastroenterology and Hepatology, Department of Medicine, Stanford University School of Medicine, Palo Alto, California, USA; 3Institute for Clinical and
Experimental Medicine, Prague, Czech Republic; 4The Kirby Institute, University of New South Wales, Sydney, NSW, Australia; 5Merck & Co., Inc., Kenilworth, NJ, USA
![0420181](../images%20/042018/041218-6/0420181.gif)
![0420182](../images%20/042018/041218-6/0420182.gif)
![0420183](../images%20/042018/041218-6/0420183.gif)
![0420184](../images%20/042018/041218-6/0420184.gif)
![0420185](../images%20/042018/041218-6/0420185.gif)
![0420186](../images%20/042018/041218-6/0420186.gif)
![0420187](../images%20/042018/041218-6/0420187.gif)
![0420188](../images%20/042018/041218-6/0420188.gif)
![0420189](../images%20/042018/041218-6/0420189.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|